Clinical management of potential bioterrorism-related conditions.

The agents most likely to be used in bioterrorism attacks are reviewed, along with the clinical syndromes they produce and their treatment.

[1]  T. Bleck,et al.  247 – Botulism (Clostridium botulinum) , 2015 .

[2]  I. Damon,et al.  135 – Orthopoxviruses: Vaccinia (Smallpox Vaccine), Variola (Smallpox), Monkeypox, and Cowpox , 2015 .

[3]  Sandra K. Martin,et al.  Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. , 2014, Vaccine.

[4]  Markus H. Antwerpen,et al.  Injectional Anthrax in Heroin Users, Europe, 2000–2012 , 2014, Emerging infectious diseases.

[5]  Theresa L. Smith,et al.  Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults , 2014, Emerging infectious diseases.

[6]  S. Arnon,et al.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. , 2014, The Journal of infectious diseases.

[7]  M. Blaser,et al.  Comprar Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition | John E. Bennett | 9781455748013 | Saunders , 2014 .

[8]  Jeanne Guillemin.  The Soviet Biological Weapons Program: A History , 2013 .

[9]  Tara Kirk Sell,et al.  Federal agency biodefense funding, FY2013-FY2014. , 2013, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[10]  D. Smee.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012. , 2013, Future virology.

[11]  M. Al-Ibrahim,et al.  Evaluation of Intravenous Anthrax Immune Globulin for Treatment of Inhalation Anthrax , 2013, Antimicrobial Agents and Chemotherapy.

[12]  M. Christian.  Biowarfare and Bioterrorism , 2013, Critical Care Clinics.

[13]  S. El-Kamary,et al.  Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. , 2013, Vaccine.

[14]  T. Rudge,et al.  Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure Prophylaxis , 2013, Clinical and Vaccine Immunology.

[15]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[16]  S. Rasmussen,et al.  Anthrax Cases in Pregnant and Postpartum Women: A Systematic Review , 2012, Obstetrics and gynecology.

[17]  R. Ahmed,et al.  Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. , 2012, The Journal of infectious diseases.

[18]  M. Doğanay,et al.  Naturally Occurring Cutaneous Anthrax: Antibiotic Treatment and Outcome , 2012, Chemotherapy.

[19]  K. Edwards,et al.  Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. , 2011, The Journal of infectious diseases.

[20]  X. Cui,et al.  Anthrax infection. , 2011, American journal of respiratory and critical care medicine.

[21]  Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. , 2011, MMWR. Morbidity and mortality weekly report.

[22]  E. Zumbrun,et al.  ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile , 2010, Drug design, development and therapy.

[23]  R. Penn.  Francisella tularensis (Tularemia) , 2010 .

[24]  P. Mead,et al.  Yersinia Species, Including Plague , 2010 .

[25]  A. Friedlander,et al.  Bacillus anthracis (Anthrax) , 2010 .

[26]  Christine Bean,et al.  Gastrointestinal anthrax after an animal-hide drumming event - New Hampshire and Massachusetts, 2009. , 2010, MMWR. Morbidity and mortality weekly report.

[27]  S. Ullrich,et al.  Raxibacumab for the treatment of inhalational anthrax. , 2009, The New England journal of medicine.

[28]  Leonard A. Smith.  Botulism and vaccines for its prevention. , 2009, Vaccine.

[29]  S. Narayan,et al.  Anthrax meningoencephalitis — Declining trends in an uncommon but catastrophic CNS infection in rural Tamil Nadu, South India , 2009, Journal of the Neurological Sciences.

[30]  M. Černá.  Beyond Anthrax: The Weaponization of Infectious Diseases , 2009 .

[31]  L. Ferrucci,et al.  Immunity from smallpox vaccine persists for decades: a longitudinal study. , 2008, The American journal of medicine.

[32]  Sandra K. Martin,et al.  Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. , 2008, JAMA.

[33]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[34]  K. McDonald,et al.  Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005. , 2007, Archives of pediatrics & adolescent medicine.

[35]  L. Rotz,et al.  A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  T. Butler,et al.  Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Douglas K Owens,et al.  Systematic Review: A Century of Inhalational Anthrax Cases from 1900 to 2005 , 2006, Annals of Internal Medicine.

[38]  J. Sejvar,et al.  Management of anthrax meningitis. , 2005, The Lancet. Infectious diseases.

[39]  Adrienne Mayor,et al.  Greek Fire, Poison Arrows & Scorpion Bombs: Biological and Chemical Warfare in the Ancient World , 2004 .

[40]  Nathaniel Hupert,et al.  Accuracy of Screening for Inhalational Anthrax after a Bioterrorist Attack , 2003, Annals of Internal Medicine.

[41]  Dori B. Reissman,et al.  Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  Tanja Popovic,et al.  Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings , 2002, Emerging infectious diseases.

[43]  Elizabeth R. Zell,et al.  Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence , 2002, Emerging infectious diseases.

[44]  Samuel D. Uretsky,et al.  Germs: Biological Weapons and America's Secret War , 2002 .

[45]  A. Levitt,et al.  Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[46]  M. Hugh-jones,et al.  The Sverdlovsk anthrax outbreak of 1979. , 1994, Science.

[47]  J. Ezzell,et al.  Postexposure prophylaxis against experimental inhalation anthrax. , 1993, The Journal of infectious diseases.

[48]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .